SOTIO and Cytune Pharma, members of the PPF Group, have commenced the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15, it was reported on Friday.
The phase I/Ib study is to assess the safety and preliminary efficacy of the product in patients with selected advanced/metastatic solid tumours.
The first patient was treated with the product at the Institute Gustave Roussy (France). The SC103 clinical trial will also enrol patients in the Vall d'Hebron cancer centre (Spain) and, subject to receiving all the necessary approvals, at the Yale Cancer Center in New Haven, Connecticut and MD Anderson Cancer Centre in Houston, Texas.
Cytune Pharma is responsible for the clinical development of SO-C101, SOTIO is sponsor of the SC103 clinical trial.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study